Adjuvant endocrine therapy for premenopausal women with early breast cancer

Ting Bao, Nancy E. Davidson

Research output: Contribution to journalArticle

Abstract

Adjuvant endocrine therapy is a pivotal component of treatment for premenopausal women with early-stage hormone receptor-positive breast cancer. Currently, the standard endocrine therapy for premenopausal women is tamoxifen; a role for ovarian suppression or ablation has also been identified. Uncertainty remains about the optimal use of endocrine therapy in this setting. The role of ovarian suppression with tamoxifen or aromatase inhibitor, the optimal duration of adjuvant endocrine therapy and the utility of biomarkers and pharmacogenetic studies to select therapy are questions worthy of further investigation.

Original languageEnglish (US)
Article number115
JournalBreast Cancer Research
Volume9
Issue number6
DOIs
StatePublished - Dec 17 2007

Fingerprint

Breast Neoplasms
Tamoxifen
Therapeutics
Aromatase Inhibitors
Uncertainty
Biomarkers
Hormones

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Adjuvant endocrine therapy for premenopausal women with early breast cancer. / Bao, Ting; Davidson, Nancy E.

In: Breast Cancer Research, Vol. 9, No. 6, 115, 17.12.2007.

Research output: Contribution to journalArticle

@article{66b44a8a0eac4b2c8772618aeac7f4b3,
title = "Adjuvant endocrine therapy for premenopausal women with early breast cancer",
abstract = "Adjuvant endocrine therapy is a pivotal component of treatment for premenopausal women with early-stage hormone receptor-positive breast cancer. Currently, the standard endocrine therapy for premenopausal women is tamoxifen; a role for ovarian suppression or ablation has also been identified. Uncertainty remains about the optimal use of endocrine therapy in this setting. The role of ovarian suppression with tamoxifen or aromatase inhibitor, the optimal duration of adjuvant endocrine therapy and the utility of biomarkers and pharmacogenetic studies to select therapy are questions worthy of further investigation.",
author = "Ting Bao and Davidson, {Nancy E.}",
year = "2007",
month = "12",
day = "17",
doi = "10.1186/bcr1830",
language = "English (US)",
volume = "9",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "6",

}

TY - JOUR

T1 - Adjuvant endocrine therapy for premenopausal women with early breast cancer

AU - Bao, Ting

AU - Davidson, Nancy E.

PY - 2007/12/17

Y1 - 2007/12/17

N2 - Adjuvant endocrine therapy is a pivotal component of treatment for premenopausal women with early-stage hormone receptor-positive breast cancer. Currently, the standard endocrine therapy for premenopausal women is tamoxifen; a role for ovarian suppression or ablation has also been identified. Uncertainty remains about the optimal use of endocrine therapy in this setting. The role of ovarian suppression with tamoxifen or aromatase inhibitor, the optimal duration of adjuvant endocrine therapy and the utility of biomarkers and pharmacogenetic studies to select therapy are questions worthy of further investigation.

AB - Adjuvant endocrine therapy is a pivotal component of treatment for premenopausal women with early-stage hormone receptor-positive breast cancer. Currently, the standard endocrine therapy for premenopausal women is tamoxifen; a role for ovarian suppression or ablation has also been identified. Uncertainty remains about the optimal use of endocrine therapy in this setting. The role of ovarian suppression with tamoxifen or aromatase inhibitor, the optimal duration of adjuvant endocrine therapy and the utility of biomarkers and pharmacogenetic studies to select therapy are questions worthy of further investigation.

UR - http://www.scopus.com/inward/record.url?scp=40349103600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40349103600&partnerID=8YFLogxK

U2 - 10.1186/bcr1830

DO - 10.1186/bcr1830

M3 - Article

C2 - 18190722

AN - SCOPUS:40349103600

VL - 9

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 6

M1 - 115

ER -